Pharmacogenomics of Type 2 Diabetes Mellitus

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  2017-10-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.5005/JP-JOURNALS-10082-01102
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients

  2016cited by this paper
• Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetesd2016. Diabetes Care 2016

  2016cited by this paper
• Differential Role of Leptin and Adiponectin in Cardiovascular System

  2015cited by this paper
• In silico Evaluation of Nonsynonymous Single Nucleotide Polymorphisms in the ADIPOQ Gene Associated with Diabetes, Obesity, and Inflammation

  2015cited by this paper
• No evidence for association of insulin receptor substrate-1 Gly972Arg variant with type 2 diabetes mellitus in a mixed-ancestry population of South Africa.

  2014cited by this paper
• Adiponectin Gene Polymorphism rs2241766 T/G Is Associated with Response to Pioglitazone Treatment in Type 2 Diabetic Patients from Southern China

  2014cited by this paper
• Recent advances in the molecular genetics of type 2 diabetes mellitus.

  2014influential reference
• Insulin Receptor Substrate-1 (IRS-1) Gly927Arg: Correlation with Gestational Diabetes Mellitus in Saudi Women

  2014cited by this paper
• Association of IRS1, CAPN10, and PPARG gene polymorphisms with type 2 diabetes mellitus in the high‐risk population of Hyderabad, India 在印度海得拉巴高风险人群中IRS1、CAPN10以及PPARG基因多态性与2型糖尿病的关系

  2014cited by this paper
• Proliferator-activated receptor gamma Pro12Ala interacts with the insulin receptor substrate 1 Gly972Arg and increase the risk of insulin resistance and diabetes in the mixed ancestry population from South Africa

  2014cited by this paper
• The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPAR&ggr; on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes

  2013cited by this paper
• Importance of Weight Loss Maintenance and Risk Prediction in the Prevention of Type 2 Diabetes: Analysis of European Diabetes Prevention Study RCT

  2013cited by this paper
• Genetic variants and the risk of gestational diabetes mellitus: a systematic review.

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013

  2013cited by this paper
• Pleiotropic Effects of Thiazolidinediones: Implications for the Treatment of Patients With Type 2 Diabetes Mellitus

  2013cited by this paper
• Metformin pathways: pharmacokinetics and pharmacodynamics

  2012cited by this paper
• The role of ATM in response to metformin treatment and activation of AMPK

  2012cited by this paper
• The C Allele of ATM rs11212617 Does Not Associate With Metformin Response in the Diabetes Prevention Program

  2012cited by this paper
• KCNQ1 variants and response to repaglinide treatment in patients with Type 2 diabetes.

  2012cited by this paper
• Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.

  2012cited by this paper
• A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts

  2012cited by this paper
• Disposition of metformin: Variability due to polymorphisms of organic cation transporters

  2012cited by this paper
• Ablation of Both Organic Cation Transporter (Oct)1 and Oct2 Alters Metformin Pharmacokinetics but Has No Effect on Tissue Drug Exposure and Pharmacodynamics

  2012cited by this paper
• Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer

  2011cited by this paper
• Impact of Positive Family History and Genetic Risk Variants on the Incidence of Diabetes

  2011cited by this paper
• The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c

  2011cited by this paper
• Discovery of a Novel Allelic Variant of CYP2C8, CYP2C8*11, in Asian Populations and Its Clinical Effect on the Rosiglitazone Disposition In Vivo

  2011cited by this paper
• Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus

  2011cited by this paper
• Optimizing the technological and informational relationship of the health care process and of the communication between physician and patient. The impact of Preventive Medicine and social marketing applied in Health Care on youth awareness–Preliminary study

  2011cited by this paper
• Variation in the ATM gene may alter glycemic response to metformin.

  2011cited by this paper
• Gestational diabetes mellitus shares polymorphisms of genes associated with insulin resistance and type 2 diabetes in the Greek population

  2011cited by this paper
• The Association Between the Peroxisome Proliferator-Activated Receptor-γ2 (PPARG2) Pro12Ala Gene Variant and Type 2 Diabetes Mellitus: A HuGE Review and Meta-Analysis

  2010cited by this paper
• NOS1AP variant associated with incidence of type 2 diabetes in calcium channel blocker users in the Atherosclerosis Risk in Communities (ARIC) study

  2010cited by this paper
• Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms

  2010influential reference
• Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program

  2010cited by this paper
• Lifestyle Intervention for Prevention of Type 2 Diabetes in Primary Health Care

  2010cited by this paper
• Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

  2010cited by this paper
• Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes

  2010cited by this paper
• Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus.

  2010cited by this paper
• Loss‐of‐Function CYP2C9 Variants Improve Therapeutic Response to Sulfonylureas in Type 2 Diabetes: A Go‐DARTS Study

  2010cited by this paper
• Pharmacogenetics of Anti-Diabetes Drugs

  2010cited by this paper
• Update of mutations in the genes encoding the pancreatic beta‐cell KATP channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism

  2009cited by this paper
• The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin

  2009cited by this paper
• The E23K Variant of KCNJ11 and the Risk for Severe Sulfonylurea-induced Hypoglycemia in Patients with Type 2 Diabetes

  2009cited by this paper
• Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study

  2009cited by this paper
• Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study

  2009cited by this paper
• Coexpression of the Type 2 Diabetes Susceptibility Gene Variants KCNJ11 E23K and ABCC8 S1369A Alter the ATP and Sulfonylurea Sensitivities of the ATP-Sensitive K+ Channel

  2009cited by this paper
• Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin

  2009cited by this paper
• Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus

  2009cited by this paper
• Translating TCF7L2: from gene to function

  2009cited by this paper
• Personalized pharmacotherapy for Type 2 diabetes mellitus.

  2009cited by this paper
• Pleiotropic effects of thiazolidinediones

  2008cited by this paper
• Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone

  2008cited by this paper
• Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients

  2008cited by this paper
• OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine

  2008cited by this paper
• Glucagon-like Peptide-1 Activation of TCF7L2-dependent Wnt Signaling Enhances Pancreatic Beta Cell Proliferation*

  2008cited by this paper
• Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin Pharmacokinetics

  2008cited by this paper
• Etoposide Induces ATM-Dependent Mitochondrial Biogenesis through AMPK Activation

  2008cited by this paper
• The association of adiponectin allele 45T/G and -11377C/G polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patients.

  2008cited by this paper
• Impact of genetic polymorphisms of leptin and TNF-α on rosiglitazone response in Chinese patients with type 2 diabetes

  2008cited by this paper
• Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea

  2008cited by this paper
• Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes

  2008cited by this paper
• Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences.

  2008cited by this paper
• Cytochrome P450 2C9 *2 and *3 Polymorphisms and the Dose and Effect of Sulfonylurea in Type II Diabetes Mellitus

  2008cited by this paper
• The WNT signalling pathway and diabetes mellitus

  2008cited by this paper
• Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers

  2008cited by this paper
• The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes

  2008cited by this paper
• Genetic variation in the NOS1AP gene is associated with the incidence of diabetes mellitus in users of calcium channel blockers

  2008cited by this paper
• Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes.

  2007cited by this paper
• Pharmacogenetics of metformin response: a step in the path toward personalized medicine.

  2007cited by this paper
• Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.

  2007cited by this paper
• Identification and Functional Characterization of Genetic Variants of Human Organic Cation Transporters in a Korean Population

  2007cited by this paper
• Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.

  2007cited by this paper
• Variation in TCF7L2 Influences Therapeutic Response to Sulfonylureas

  2007influential reference
• AICAR induces phosphorylation of AMPK in an ATM-dependent, LKB1-independent manner

  2007cited by this paper
• Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.

  2006cited by this paper
• Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin

  2006cited by this paper
• The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.

  2006cited by this paper
• Polymorphisms of insulin receptor substrate 1 and beta3-adrenergic receptor genes in gestational diabetes and normal pregnancy.

  2006influential reference
• The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.

  2006cited by this paper
• Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

  2006cited by this paper
• Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes.

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Association of insulin receptor substrate-1 G972R variant with baseline characteristics of the patients with gestational diabetes mellitus.

  2006cited by this paper
• Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.

  2006cited by this paper
• A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness.

  2005cited by this paper
• The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes.

  2005cited by this paper
• Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.

  2005cited by this paper
• Effects of Pro12Ala polymorphism of peroxisome proliferator‐activated receptor γ2 gene on rosiglitazone response in type 2 diabetes

  2005cited by this paper
• The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.

  2005cited by this paper
• Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective.

  2005cited by this paper
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25.

  2004cited by this paper
• Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region.

  2004cited by this paper
• Linkage of the metabolic syndrome to 1q23-q31 in Hispanic families: the Insulin Resistance Atherosclerosis Study Family Study.

  2004cited by this paper
• The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.

  2004cited by this paper
• Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions

  2004cited by this paper
• Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1).

  2004cited by this paper
• Genome-wide Scan for Metabolic Syndrome and Related Quantitative Traits in Hong Kong Chinese and Confirmation of a Susceptibility Locus on Chromosome 1 q 21-q 25

  2004cited by this paper

• Pharmacogenomic Advancements For The Management Of Diabetes Mellitus

  2020cites this paper